Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of fecal microbiota transplantation on quality of life in patients with chronic pouchitis: a post hoc analysis of the MicroPouch trial.

Therapeutic advances in gastroenterology·2026
Same author

Municipal intermediate care services in Denmark and Norway: a cross-country comparative analysis.

Scandinavian journal of primary health care·2026
Same author

Socioeconomic disparities and mortality among acute patients with sepsis: a retrospective Danish cohort study.

BMJ open·2026
Same author

Tokyo Guidelines' performance in predicting acute cholangitis among emergency department patients.

Danish medical journal·2026
Same author

Clinical Frailty Scale scores of older patients admitted to an emergency department.

Danish medical journal·2026
Same author

Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multi-centre RCT.

European thyroid journal·2025
Same journal

The quantification and epistemology of medicines use and polypharmacy tested in an observational study.

British journal of clinical pharmacology·2026
Same journal

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study.

British journal of clinical pharmacology·2026
Same journal

Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.

British journal of clinical pharmacology·2026
Same journal

Cardiovascular and neuroendocrine dynamics in antibiotic dose individualization in intensive care.

British journal of clinical pharmacology·2026
Same journal

Safety of swallowed corticosteroids and their influence on the hypothalamic-pituitary-adrenal gland axis and on markers of bone resorption and formation in patients with eosinophilic esophagitis.

British journal of clinical pharmacology·2026
Same journal

A regulatory perspective on the first approved EU application to reformulate an inhaled medicine with a gas propellant with reduced global warming potential.

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Videos

Do statins protect against upper gastrointestinal bleeding?

Sinem Ezgi Gulmez1, Annmarie Touborg Lassen, Claus Aalykke

  • 1Research Unit of Clinical Pharmacology, University of Southern Denmark, Odense, Denmark. egulmez@health.sdu.dk

British Journal of Clinical Pharmacology
|April 18, 2009
PubMed
Summary
This summary is machine-generated.

Statins do not prevent upper gastrointestinal bleeding (UGB). However, a potential protective effect was observed when statins were used concurrently with low-dose aspirin.

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Gastroenterology
  • Pharmacology

Background:

  • A previous study suggested statins might protect against upper gastrointestinal bleeding (UGB).
  • Statins are widely prescribed cholesterol-lowering medications.
  • The potential gastroprotective effects of statins require further investigation, especially in combination with other medications.

Purpose of the Study:

  • To evaluate the effect of statin use on acute nonvariceal upper gastrointestinal bleeding (UGB).
  • To assess the impact of statin use in combination with low-dose aspirin and other antithrombotic drugs on UGB.
  • To clarify the relationship between statin therapy and the risk of serious UGB.

Main Methods:

  • A population-based case-control study was conducted in Denmark.
  • 3,652 cases of serious UGB were compared with 36,502 matched controls.
  • Drug exposure and medical history were analyzed using prescription databases and patient registers, with confounders controlled by logistic regression.

Main Results:

  • Statin use was not associated with a reduced risk of UGB (OR 0.94 for current use).
  • Recent or past statin use showed no protective effect, with odds ratios of 1.40 and 1.42, respectively.
  • A borderline significant protective effect was observed for concurrent users of statins and low-dose aspirin (OR 0.43).

Conclusions:

  • Statins do not appear to prevent upper gastrointestinal bleeding.
  • A possible protective effect of statins against UGB may exist for patients concurrently using low-dose aspirin.
  • Further research is warranted to confirm the interaction between statins and low-dose aspirin in preventing UGB.